Bayesian clinical trial designs are increasingly common; given their promotion by the US Food and Drug Administration, the future use of the Bayesian approach will only continue to increase. Innovations are possible when using the Bayesian approach
Alzheimer’s disease is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual decline in intellectual ability. The accumulation of beta-amyloid (Aβ) peptides is assessed to be one of the essential neuropathological pillars of the disorder, and its dishomeostasis plays an essential
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the main cause of dementia, with an estimated prevalence of 50 million people worldwide that is projected to triple by 2050. Masitinib is an orally administered
Alzheimer’s Disease (AD) is a debilitating disease that leads to severe cognitive impairment and functional decline.NRF-2 has been identified in modulating the effects of inflammation and oxidative stress in AD. Activation of NRF-2 leads to an increased
Aphasia affects many stroke survivors; therefore, effective treatments are urgently needed. Preliminary clinical findings have suggested an association between contralateral C7–C7 cross nerve transfer and recovery from chronic
Post-stroke aphasia (PSA) is an acquired communication disease caused by cerebrovascular disease that damages the language center of the dominant hemisphere of the brain. Patients with PSA usually have difficulty remembering words
Maximize the informational quality of your email inbox by selectively subscribing to evidence-based health and wellness resources that are informed by rigorous scientific research and medical expertise.
Your privacy is important to us
© 2020-2022 HealthSciaxis a Sciaxis Company. All rights reserved. Our website services, content, and products are for informational purposes only. HealthSciaxis does not provide medical advice, diagnosis, or treatment. See additional information.
